248 related articles for article (PubMed ID: 31362764)
1. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.
Cheung LH; Zhao Y; Alvarez-Cienfuegos A; Mohamedali KA; Cao YJ; Hittelman WN; Rosenblum MG
J Exp Clin Cancer Res; 2019 Jul; 38(1):332. PubMed ID: 31362764
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B.
Alvarez de Cienfuegos A; Cheung LH; Mohamedali KA; Whitsett TG; Winkles JA; Hittelman WN; Rosenblum MG
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958685
[TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu.
Cao Y; Mohamedali KA; Marks JW; Cheung LH; Hittelman WN; Rosenblum MG
Mol Cancer Ther; 2013 Jun; 12(6):979-91. PubMed ID: 23493312
[TBL] [Abstract][Full Text] [Related]
4. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.
Zhou H; Mohamedali KA; Gonzalez-Angulo AM; Cao Y; Migliorini M; Cheung LH; LoBello J; Lei X; Qi Y; Hittelman WN; Winkles JA; Tran NL; Rosenblum MG
Mol Cancer Ther; 2014 Nov; 13(11):2688-705. PubMed ID: 25239934
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents.
Liu Y; Cheung LH; Hittelman WN; Rosenblum MG
Mol Cancer Ther; 2003 Dec; 2(12):1341-50. PubMed ID: 14707275
[TBL] [Abstract][Full Text] [Related]
6. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
[TBL] [Abstract][Full Text] [Related]
7. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
8. Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition.
Dälken B; Giesübel U; Knauer SK; Wels WS
Cell Death Differ; 2006 Apr; 13(4):576-85. PubMed ID: 16179940
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells.
Liu Y; Cheung LH; Thorpe P; Rosenblum MG
Mol Cancer Ther; 2003 Oct; 2(10):949-59. PubMed ID: 14578460
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts.
Balandin TG; Edelweiss E; Andronova NV; Treshalina EM; Sapozhnikov AM; Deyev SM
Invest New Drugs; 2011 Feb; 29(1):22-32. PubMed ID: 19789841
[TBL] [Abstract][Full Text] [Related]
11. EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells.
Oberoi P; Jabulowsky RA; Bähr-Mahmud H; Wels WS
PLoS One; 2013; 8(4):e61267. PubMed ID: 23573299
[TBL] [Abstract][Full Text] [Related]
12. The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth.
Mohamedali KA; Cao Y; Cheung LH; Hittelman WN; Rosenblum MG
Mol Cancer Ther; 2013 Oct; 12(10):2055-66. PubMed ID: 23858102
[TBL] [Abstract][Full Text] [Related]
13. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
14. A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors.
Qian X; Shi Z; Qi H; Zhao M; Huang K; Han D; Zhou J; Liu C; Liu Y; Lu Y; Yuan X; Zhao J; Kang C
Theranostics; 2019; 9(25):7616-7627. PubMed ID: 31695790
[TBL] [Abstract][Full Text] [Related]
15. Surface charge-modification prevents sequestration and enhances tumor-cell specificity of a recombinant granzyme B-TGFα fusion protein.
Jabulowsky RA; Oberoi P; Bähr-Mahmud H; Dälken B; Wels WS
Bioconjug Chem; 2012 Aug; 23(8):1567-76. PubMed ID: 22759275
[TBL] [Abstract][Full Text] [Related]
16. Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin.
Kanatani I; Lin X; Yuan X; Manorek G; Shang X; Cheung LH; Rosenblum MG; Howell SB
Cancer Chemother Pharmacol; 2011 Oct; 68(4):979-90. PubMed ID: 21327682
[TBL] [Abstract][Full Text] [Related]
17. Fusion of apoptosis-related protein Cytochrome c with anti-HER-2 single-chain antibody targets the suppression of HER-2+ breast cancer.
Lu D; Guo Y; Hu Y; Wang M; Li C; Gangrade A; Chen J; Zheng Z; Guo J
J Cell Mol Med; 2021 Nov; 25(22):10638-10649. PubMed ID: 34697906
[TBL] [Abstract][Full Text] [Related]
18. A novel expression and purification system for the production of enzymatic and biologically active human granzyme B.
Gehrmann M; Doss BT; Wagner M; Zettlitz KA; Kontermann RE; Foulds G; Pockley AG; Multhoff G
J Immunol Methods; 2011 Aug; 371(1-2):8-17. PubMed ID: 21723287
[TBL] [Abstract][Full Text] [Related]
19. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
[TBL] [Abstract][Full Text] [Related]
20. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
